



ABOLOGIX selected as one of the top 50 start ups in french-speaking Switzerland

- **ABOLOGIX is featured in the renowned swiss magazine “Bilan” as one of the most promising start ups in the swiss start up ecosystem**
- **The company has been invited to present its investment case in a future event to be held in Lausanne, Switzerland**

Geneva, Switzerland, December 18, 2019.

Abologix has received recognition in “Bilan” as one of the most promising swiss start-ups in the french speaking cantons of Switzerland. The company has been invited to address a group of potential investors in a future meeting to be held in Lausanne, Switzerland.

About Abologix

Abologix is a pre-clinical stage biopharmaceutical company developing best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule **JAM-C** and the extracellular matrix-related protein **Olfactomedin-like protein 3 (Olfml3)** for the treatment of hematological and solid cancers. The company is based in Geneva (Switzerland) and it is a spin-out from the laboratories of Profs. Beat Imhof and Thomas Matthes at the University of Geneva and the Hôpitaux Universitaires de Genève.

Contact Information

Ignacio Faus, Chairman of the Board

Abologix. Sàrl

ignaciofaus@abologix.com